4,300
Participants
Start Date
August 30, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration
VeriSee DR is an AI-assisted diagnosis screening tool for diabetic retinopathy, the software received medical device license approval from the TFDA in 2020 (MOHW-MD-No.006966). VeriSee AMD is an AI-assisted diagnosis screening tool for age-related macular degeneration, the software also received medical device license approval from the TFDA in 2022 (MOHW-MD-No.007652).
Standard fundus photography with physician interpretation
The control group will undergo the fundus photography without AI-functionality, with reports interpreted solely by physicians. Participants must schedule a follow-up visit to receive their results.
National Taiwan University Hospital, Taipei
Fu Jen Catholic University Hospital
OTHER
Min-Sheng General Hospital
OTHER
Ministry of Health and Welfare, Taiwan
OTHER_GOV
National Taiwan University Hospital
OTHER